LT5215B - Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti - Google Patents

Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti Download PDF

Info

Publication number: LT5215B
Authority: LT; Lithuania
Prior art keywords: composition; matrix metalloproteinases; matrix; diseases; ascorbic acid
Prior art date: 2002-01-08

Application number

LT2004074A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2004074A (en

Inventor

Matthias Rath

Shrirang Netke

Vadim Ivanov

Waheed Roomi

Aleksandra Niedzwiecki

Original Assignee

Matthias Rath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-08

Filing date

2004-08-05

Publication date

2005-05-25

2004-08-05 Application filed by Matthias Rath filed Critical Matthias Rath

2004-12-27 Publication of LT2004074A publication Critical patent/LT2004074A/xx

2005-05-25 Publication of LT5215B publication Critical patent/LT5215B/lt

Links

239000000203 mixture Substances 0.000 title claims abstract description 32
108010000684 Matrix Metalloproteinases Proteins 0.000 title claims abstract description 24
102000002274 Matrix Metalloproteinases Human genes 0.000 title claims abstract description 24
201000010099 disease Diseases 0.000 title claims abstract description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 21
230000001613 neoplastic effect Effects 0.000 title claims abstract description 13
230000002401 inhibitory effect Effects 0.000 title description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 80
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 44
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 40
239000004472 Lysine Substances 0.000 claims abstract description 40
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 40
239000011668 ascorbic acid Substances 0.000 claims abstract description 40
229960005070 ascorbic acid Drugs 0.000 claims abstract description 39
230000000694 effects Effects 0.000 claims abstract description 10
239000003963 antioxidant agent Substances 0.000 claims description 14
235000006708 antioxidants Nutrition 0.000 claims description 14
230000003078 antioxidant effect Effects 0.000 claims description 11
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 7
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
210000002744 extracellular matrix Anatomy 0.000 claims description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
235000019152 folic acid Nutrition 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 4
239000011724 folic acid Substances 0.000 claims description 4
239000002243 precursor Substances 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
108010024636 Glutathione Proteins 0.000 claims description 3
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
229940093797 bioflavonoids Drugs 0.000 claims description 3
235000021466 carotenoid Nutrition 0.000 claims description 3
150000001747 carotenoids Chemical class 0.000 claims description 3
229960000304 folic acid Drugs 0.000 claims description 3
229960003180 glutathione Drugs 0.000 claims description 3
229910052711 selenium Inorganic materials 0.000 claims description 3
239000011669 selenium Substances 0.000 claims description 3
229930003799 tocopherol Natural products 0.000 claims description 3
239000011732 tocopherol Substances 0.000 claims description 3
125000002640 tocopherol group Chemical class 0.000 claims description 3
235000019149 tocopherols Nutrition 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
208000035473 Communicable disease Diseases 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims description 2
208000025966 Neurological disease Diseases 0.000 claims description 2
229960004203 carnitine Drugs 0.000 claims description 2
235000019136 lipoic acid Nutrition 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
229960002663 thioctic acid Drugs 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
229940040064 ubiquinol Drugs 0.000 claims description 2
QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 5
102000005741 Metalloproteases Human genes 0.000 claims 2
108010006035 Metalloproteases Proteins 0.000 claims 2
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 2
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
239000011159 matrix material Substances 0.000 claims 2
PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 1
PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 1
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims 1
XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims 1
229940072107 ascorbate Drugs 0.000 claims 1
230000007850 degeneration Effects 0.000 claims 1
LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims 1
235000012734 epicatechin Nutrition 0.000 claims 1
DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims 1
229940014144 folate Drugs 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
229930003802 tocotrienol Natural products 0.000 claims 1
239000011731 tocotrienol Substances 0.000 claims 1
229940068778 tocotrienols Drugs 0.000 claims 1
235000019148 tocotrienols Nutrition 0.000 claims 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 39
235000005487 catechin Nutrition 0.000 abstract description 23
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract description 23
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 17
229950001002 cianidanol Drugs 0.000 abstract description 10
-1 catechin compound Chemical class 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 54
108010082117 matrigel Proteins 0.000 description 20
206010028980 Neoplasm Diseases 0.000 description 18
201000011510 cancer Diseases 0.000 description 17
150000001765 catechin Chemical class 0.000 description 16
206010006187 Breast cancer Diseases 0.000 description 14
208000026310 Breast neoplasm Diseases 0.000 description 14
239000002609 medium Substances 0.000 description 13
244000269722 Thea sinensis Species 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 8
235000009569 green tea Nutrition 0.000 description 8
201000001441 melanoma Diseases 0.000 description 8
238000000034 method Methods 0.000 description 8
230000035515 penetration Effects 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
238000003556 assay Methods 0.000 description 7
239000000039 congener Substances 0.000 description 7
230000002195 synergetic effect Effects 0.000 description 7
235000018977 lysine Nutrition 0.000 description 6
150000008442 polyphenolic compounds Chemical class 0.000 description 6
235000013930 proline Nutrition 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 4
230000009702 cancer cell proliferation Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
235000012041 food component Nutrition 0.000 description 4
239000005417 food ingredient Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
235000013824 polyphenols Nutrition 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
230000002001 anti-metastasis Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000004709 cell invasion Effects 0.000 description 2
238000004581 coalescence Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
150000002206 flavan-3-ols Chemical class 0.000 description 2
235000011987 flavanols Nutrition 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000003642 reactive oxygen metabolite Substances 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
PBZMVAYHJDFHIR-UHFFFAOYSA-N 2-phenyl-3,4-dihydrochromene-2,3-diol Chemical class OC1CC2=CC=CC=C2OC1(O)C1=CC=CC=C1 PBZMVAYHJDFHIR-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
150000000996 L-ascorbic acids Chemical class 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
201000009053 Neurodermatitis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
150000002668 lysine derivatives Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
235000009048 phenolic acids Nutrition 0.000 description 1
150000007965 phenolic acids Chemical class 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
229960002429 proline Drugs 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
235000020095 red wine Nutrition 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940065287 selenium compound Drugs 0.000 description 1
150000003343 selenium compounds Chemical class 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
235000013616 tea Nutrition 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)

LT2004074A 2002-01-08 2004-08-05 Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti LT5215B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/041,427 US6939860B2 (en)	2002-01-08	2002-01-08	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds

Publications (2)

Publication Number	Publication Date
LT2004074A LT2004074A (en)	2004-12-27
LT5215B true LT5215B (lt)	2005-05-25

Family

ID=21916454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2004074A LT5215B (lt)	2002-01-08	2004-08-05	Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti

Country Status (29)

Country	Link
US (3)	US6939860B2 (de)
EP (1)	EP1463498B1 (de)
JP (1)	JP4144800B2 (de)
KR (1)	KR20050005408A (de)
CN (1)	CN1612731A (de)
AT (1)	ATE439833T1 (de)
AU (2)	AU2002244690A1 (de)
BR (1)	BR0208052A (de)
CA (1)	CA2469162A1 (de)
CZ (1)	CZ2004853A3 (de)
DE (1)	DE60233433D1 (de)
EE (1)	EE200400031A (de)
ES (1)	ES2332126T3 (de)
HR (1)	HRP20040705A2 (de)
HU (1)	HUP0402421A3 (de)
IL (1)	IL162384A0 (de)
LT (1)	LT5215B (de)
LV (1)	LV13249B (de)
MX (1)	MXPA04006627A (de)
NO (1)	NO20033949L (de)
NZ (1)	NZ533353A (de)
PL (1)	PL371205A1 (de)
RU (1)	RU2284185C2 (de)
SI (1)	SI21871A (de)
SK (1)	SK2772004A3 (de)
TR (1)	TR200401669T1 (de)
UA (1)	UA78979C2 (de)
WO (1)	WO2003057211A1 (de)
ZA (1)	ZA200404915B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8669282B2 (en) *	2000-10-31	2014-03-11	Hill's Pet Nutrition, Inc.	Companion animal compositions including lipoic acid and methods of use thereof
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
US20050079234A1 (en) *	2003-08-27	2005-04-14	Chiang Yang Chi	Compositions comprising herbs and method for immunomodulation
KR20050070385A (ko) *	2003-12-30	2005-07-07	(주)현덕비엔티	폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물
US20080160099A1 (en) *	2004-11-10	2008-07-03	The Trustees Of Columbia University In The City Of New York	Methods For Treating or Preventing a Vascular Disease
ES2246737B1 (es) *	2005-06-09	2006-12-01	Jose Juan Rodriguez Jerez	"composicion farmaceutica que comprende lisina y usos correspondientes".
EP1965779B1 (de) *	2005-12-29	2014-07-02	Mitsui Norin Co., Ltd	Zusammensetzungen und verfahren zur sensibilisierung von methicillin-resistentem staphylococcus aureus gegen oxacillin
US20070265211A1 (en) *	2006-05-12	2007-11-15	Matthias Rath	Novel composition and method effective in inhibiting the atherogenic process
US20100055205A1 (en) *	2008-08-29	2010-03-04	Kristina Mains	Functional consumable compositions for promoting skin health and methods for using the same
EP2179722A1 (de) *	2008-10-24	2010-04-28	Heinrich-Pette-Institut für experimentelle Virologie und Immunologie	Topische Formation zur Vorbeugung der sexuellen Übertragung von Virusinfektionen
MX2011004678A (es)	2008-11-04	2011-10-11	Vymedic Llc	Formulaciones complementarias antivirales.
JP4786000B2 (ja) *	2009-10-16	2011-10-05	株式会社カネカ	還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物
ES2694582T3 (es) *	2011-01-31	2018-12-21	Lucolas-M.D. Ltd.	Combinaciones de inhibidores de aromatasa y antioxidantes
KR101829330B1 (ko)	2011-04-13	2018-02-20	(주)아모레퍼시픽	염증성 피부 노화 억제 물질 스크리닝 방법
CN102526170B (zh) *	2011-12-31	2015-04-29	许学志	抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用
BE1023772B9 (fr) *	2013-05-17	2017-08-02	Valore	Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
CN104096058A (zh) *	2014-07-02	2014-10-15	胥玲	一种治疗扩张型心肌病的中药药丸
BE1022579A9 (fr) *	2014-11-10	2016-10-06	Valore	Composition antimétastatique comprenant au moins un composé de type flavanol
IT202200013867A1 (it) *	2022-06-30	2023-12-30	Lo Li Pharma Srl	Composizione per il trattamento dell’ infezione da papilloma virus (hpv)
CN118831080B (zh) *	2024-09-24	2024-11-22	上海交通大学医学院附属仁济医院	5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
HUP9903916A3 (en) *	1996-08-28	2001-06-28	Procter And Gamble Co Cincinna	Phosphinic acid amides and pharmaceutical compositions containing the same
US5962517A (en) *	1997-01-31	1999-10-05	Murad; Howard	Pharmaceutical compositions and methods for treating acne
US5817695A (en) *	1997-12-24	1998-10-06	Pellico; Michael A.	Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6428818B1 (en) *	1999-03-30	2002-08-06	Purdue Research Foundation	Tea catechin formulations and processes for making same
KR20020016833A (ko)	1999-06-15	2002-03-06	뉴트리-로직스, 인크.	발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
EP1480973B1 (de) *	2002-02-25	2008-02-13	Boehringer Ingelheim Pharmaceuticals Inc.	1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen

2002
- 2002-01-08 US US10/041,427 patent/US6939860B2/en not_active Expired - Fee Related
- 2002-01-31 EE EEP200400031A patent/EE200400031A/xx unknown
- 2002-01-31 WO PCT/EP2002/001005 patent/WO2003057211A1/en not_active Ceased
- 2002-01-31 RU RU2004124047/15A patent/RU2284185C2/ru not_active IP Right Cessation
- 2002-01-31 AT AT02712877T patent/ATE439833T1/de active
- 2002-01-31 KR KR10-2004-7010603A patent/KR20050005408A/ko not_active Ceased
- 2002-01-31 PL PL02371205A patent/PL371205A1/xx unknown
- 2002-01-31 SI SI200220038A patent/SI21871A/sl not_active IP Right Cessation
- 2002-01-31 ES ES02712877T patent/ES2332126T3/es not_active Expired - Lifetime
- 2002-01-31 NZ NZ533353A patent/NZ533353A/en unknown
- 2002-01-31 JP JP2003557569A patent/JP4144800B2/ja not_active Expired - Fee Related
- 2002-01-31 DE DE60233433T patent/DE60233433D1/de not_active Expired - Lifetime
- 2002-01-31 IL IL16238402A patent/IL162384A0/xx not_active IP Right Cessation
- 2002-01-31 CZ CZ2004853A patent/CZ2004853A3/cs unknown
- 2002-01-31 TR TR2004/01669T patent/TR200401669T1/xx unknown
- 2002-01-31 EP EP02712877A patent/EP1463498B1/de not_active Expired - Lifetime
- 2002-01-31 MX MXPA04006627A patent/MXPA04006627A/es active IP Right Grant
- 2002-01-31 BR BR0208052-4A patent/BR0208052A/pt not_active IP Right Cessation
- 2002-01-31 UA UA20040705480A patent/UA78979C2/uk unknown
- 2002-01-31 HR HR20040705A patent/HRP20040705A2/hr not_active Application Discontinuation
- 2002-01-31 CN CNA028269543A patent/CN1612731A/zh active Pending
- 2002-01-31 AU AU2002244690A patent/AU2002244690A1/en not_active Abandoned
- 2002-01-31 SK SK277-2004A patent/SK2772004A3/sk not_active Application Discontinuation
- 2002-01-31 HU HU0402421A patent/HUP0402421A3/hu unknown
- 2002-01-31 CA CA002469162A patent/CA2469162A1/en not_active Abandoned
2003
- 2003-09-05 NO NO20033949A patent/NO20033949L/no not_active Application Discontinuation
2004
- 2004-06-22 ZA ZA200404915A patent/ZA200404915B/en unknown
- 2004-08-05 LT LT2004074A patent/LT5215B/lt unknown
- 2004-09-06 LV LVP-04-88A patent/LV13249B/en unknown
- 2004-09-15 US US10/942,723 patent/US20050032715A1/en not_active Abandoned
2005
- 2005-08-24 US US11/211,389 patent/US20050281794A1/en not_active Abandoned
2008
- 2008-07-16 AU AU2008203157A patent/AU2008203157A1/en not_active Abandoned

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AHMAD N ET AL.: "Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells", J NATL CANCER INST, 1997, pages 1881 - 1886
CAO Y, CAO R.: "Angiogenesis inhibited by drinking tea", NATURE, 1999, pages 381, XP000953295, DOI: doi:10.1038/18793
CHEN L, LEE MJ, LI H, YANG CS.: "Absorption, distribution, elimination of tea polyphenols in rats", DRUG METAB DISPOS., 1997, pages 1045 - 1050, XP055259807
CHOW H. H., CAI Y. ET AL.: "Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E", CANCER EPIDEMIOL. BIOMARK. PREV., 2001, pages 53 - 58, XP002366662
JANKUN J. ET AL.: "Why drinking green tea could prevent cancer", NATURE, 1997, pages 567
JENNIFER RC BELL ET AL.: "(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine1,2,3", AMERICAN SOCIETY FOR CLINICAL NUTRITION, 2000, pages 103 - 108
MUKHTAR H, AHMAD N.: "Tea polyphenols: prevention of cancer and optimizing health.", AM J CLIN NUTR., 2000, pages 1698 - 1702
NCI, DCPC CHEMOPREVENTION BRANCH AND AGENT DE: "Clinical development plan: Tea extracts, green tea polyphenols, epigallocatechin gallate.", J. CELL BIOCHEM, 1996, pages 236 - 257
YANG C. S., CHEN L. ET AL.: "Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers", CANCER EPIDEMIOL. BIOMARK. PREV., 1998, pages 351 - 354

Also Published As

Publication number	Publication date
UA78979C2 (en)	2007-05-10
SK2772004A3 (en)	2004-12-01
RU2284185C2 (ru)	2006-09-27
NO20033949D0 (no)	2003-09-05
ZA200404915B (en)	2006-07-26
ES2332126T3 (es)	2010-01-27
US20050032715A1 (en)	2005-02-10
EP1463498A1 (de)	2004-10-06
US20030130201A1 (en)	2003-07-10
JP4144800B2 (ja)	2008-09-03
DE60233433D1 (de)	2009-10-01
TR200401669T1 (tr)	2007-01-22
AU2008203157A1 (en)	2008-08-07
CZ2004853A3 (cs)	2004-12-15
EP1463498B1 (de)	2009-08-19
LT2004074A (en)	2004-12-27
CN1612731A (zh)	2005-05-04
NZ533353A (en)	2007-04-27
JP2005513166A (ja)	2005-05-12
CA2469162A1 (en)	2003-07-17
RU2004124047A (ru)	2005-04-20
LV13249B (en)	2005-07-20
BR0208052A (pt)	2005-01-04
HUP0402421A3 (en)	2008-02-28
IL162384A0 (en)	2005-11-20
MXPA04006627A (es)	2004-11-10
WO2003057211A1 (en)	2003-07-17
US20050281794A1 (en)	2005-12-22
HUP0402421A2 (hu)	2005-07-28
ATE439833T1 (de)	2009-09-15
KR20050005408A (ko)	2005-01-13
EE200400031A (et)	2004-04-15
PL371205A1 (en)	2005-06-13
HRP20040705A2 (en)	2004-10-31
SI21871A (sl)	2006-04-30
US6939860B2 (en)	2005-09-06
AU2002244690A1 (en)	2003-07-24
NO20033949L (no)	2003-11-04

Publication	Publication Date	Title
AU2008203157A1 (en)	2008-08-07	Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
US7041699B2 (en)	2006-05-09	Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
Chai et al.	2003	Contribution of hydrogen peroxide to the cytotoxicity of green tea and red wines
Bonfili et al.	2008	Natural polyphenols as proteasome modulators and their role as anti‐cancer compounds
US6713506B2 (en)	2004-03-30	Tea polyphenol esters and analogs thereof for cancer prevention and treatment
KR101992821B1 (ko)	2019-06-25	골질환 예방 또는 치료용 약학 조성물
KR20050086954A (ko)	2005-08-30	항증식성 화합물
Wu et al.	2013	Alternanthera paronychioides protects pancreatic β-cells from glucotoxicity by its antioxidant, antiapoptotic and insulin secretagogue actions
JPWO2006004110A1 (ja)	2008-04-24	リパーゼ阻害剤
KR20160127861A (ko)	2016-11-07	메틸화카테킨을 유효성분으로 함유하는 암세포의 성장억제용 조성물
KR101879398B1 (ko)	2018-07-18	망고스틴 추출물 및 프로폴리스 추출물을 포함하는 골형성 촉진용 조성물 및 이의 제조방법
EP1874354A1 (de)	2008-01-09	Nährstoffzusammensetzung mit polyphenolen von grünem tee zur behandlung von osteosarkom
HK1076606A (en)	2006-01-20	Composition inhibitingmatrix-metallproteinases for the treatmentof neoplastic diseases
Gonta et al.	2008	Establishment of the antioxidant/antiradical activity of the inhibitors using the DPPH–radical
HK1086489B (en)	2009-01-23	A nutrient pharmaceutical formulation comprising polyphenols and use in the manufacture of a medicament for the treatment of cancer
Cristiano et al.	2013	Cocoa Powder Triggers Neuroprotective and Preventive Effects in a Human Alzheimer 0 s Disease Model by Modulating BDNF Signaling Pathway
WO2006108429A1 (en)	2006-10-19	Nutrient composition for treating sarcoma and prostate cancer